The Food and Drug Administration (FDA) granted traditional approval to Imdelltra (tarlatamab-dlle) for adult patients with ...

Future SCLC treatment may involve combining T-cell engagers with immune checkpoint inhibitors to enhance patient outcomes.

New artificial intelligence technology is helping diagnose the U.S.’s most deadly cancer sooner, greatly improving the ...

1. Food and Drug Administration. FDA grants traditional approval to tarlatamab-dlle for extensive-stage small-cell lung cancer. FDA. November 19, 2025. Accessed November 19, 2025.

October brought several updates in the lung cancer field, ranging from notable trial results to patient-centered perspectives ...

Please provide your email address to receive an email when new articles are posted on . Treatment with durvalumab improved PFS and OS compared with placebo. Incidence of grade 3 or grade 4 adverse ...

Amgen's Imdelltra received full approval from the Food and Drug Administration for use in patients with lung cancer. The biotechnology company said Wednesday Imdelltra received approval for adult ...

Chemoradiotherapy (CRT) was preferred to radiotherapy alone in patients older than 65 years who had stage II nonsurgical non–small cell lung cancer (NSCLC), as overall survival (OS) and ...

Small cell lung cancer (SCLC) is rarer than non-small cell lung cancer (NSCLC) but tends to be more difficult to treat. SCLC can be more resistant and aggressive than other cancers, which can increase ...

Stage 3 lung cancer is considered locally advanced with spread in the region near the site. Survival rates for stage 3 non-small cell lung cancer (NSCLC) range from as high as 36% to as low as 13%, ...

Diagnosed with small-cell lung cancer at 28, Montessa Lee has defied the odds for nearly 20 years, surviving a disease with a ...

Please provide your email address to receive an email when new articles are posted on . Patients with limited-stage small-cell lung cancer had OS, PFS improvements on durvalumab compared with placebo ...